Radiopharm Theranostics (ASX:RAD) has announced that Dr Shannon Turley and her team of more than 30 scientists published an analysis of the role of LRRC15 in cancer growth.
The report was published by prestigious scientific journal on 28 September 2022.
Dr Turley’s team showed that the LRRC15 proteins on cancer associated fibroblasts (CAFs) are essential for protecting tumour cells from the immune system, and are thus essential for allowing tumours to grow.
The research team downgraded the expression of the LRRC15 protein in aggressive tumour cells by using a very elegant knock out mouse model they recently developed.
Radiopharm Theranostics said it plans to replicate their work in the clinic with a monoclonal antibody against LRRC15. That antibody, called DUNP19, will be labelled with a high energy radioactive isotope.
The company said that radiolabelled DUNP19 (RAD 502) should kill the tumour cells directly, and perhaps as importantly, the surrounding cells in the tumour microenvironment (TME) that protects the cancer from being attacked by the immune system. T
“The publication in Nature significantly strengthens already robust assessments of LRRC15 as a biomarker for aggressive malignancies,” it said.
